-DOCSTART- -X- O
In -X- _ O
the -X- _ O
USA -X- _ O
and -X- _ O
other -X- _ O
western -X- _ O
nations -X- _ O
, -X- _ O
respiratory -X- _ B-Intervention
syncytial -X- _ I-Intervention
virus -X- _ I-Intervention
is -X- _ O
one -X- _ O
of -X- _ O
the -X- _ O
most -X- _ O
commonly -X- _ O
encountered -X- _ O
respiratory -X- _ O
viruses -X- _ O
among -X- _ O
patients -X- _ B-Patient
who -X- _ I-Patient
have -X- _ I-Patient
been -X- _ I-Patient
diagnosed -X- _ I-Patient
with -X- _ I-Patient
a -X- _ I-Patient
hematologic -X- _ I-Patient
malignancy -X- _ I-Patient
or -X- _ I-Patient
who -X- _ I-Patient
have -X- _ I-Patient
undergone -X- _ I-Patient
a -X- _ I-Patient
stem -X- _ I-Patient
cell -X- _ I-Patient
transplant. -X- _ I-Patient
Multiple -X- _ O
studies -X- _ O
have -X- _ O
been -X- _ O
performed -X- _ O
to -X- _ O
evaluate -X- _ O
the -X- _ O
complications -X- _ O
associated -X- _ O
with -X- _ O
respiratory -X- _ B-Intervention
syncytial -X- _ I-Intervention
virus -X- _ I-Intervention
infections. -X- _ O
Other -X- _ O
studies -X- _ O
have -X- _ O
evaluated -X- _ O
therapeutic -X- _ O
agents -X- _ O
and -X- _ O
strategies -X- _ O
in -X- _ O
which -X- _ O
these -X- _ O
agents -X- _ O
can -X- _ O
be -X- _ O
used. -X- _ O
There -X- _ O
have -X- _ O
also -X- _ O
been -X- _ O
numerous -X- _ O
reports -X- _ O
of -X- _ O
outbreaks -X- _ O
in -X- _ O
bone -X- _ O
marrow -X- _ O
transplant -X- _ O
units -X- _ O
and -X- _ O
oncology -X- _ O
wards -X- _ O
, -X- _ O
where -X- _ O
infection -X- _ O
control -X- _ O
measures -X- _ O
have -X- _ O
been -X- _ O
invaluable -X- _ O
in -X- _ O
controlling -X- _ O
the -X- _ O
spread -X- _ O
of -X- _ O
disease. -X- _ O
However -X- _ O
, -X- _ O
despite -X- _ O
these -X- _ O
novel -X- _ O
approaches -X- _ O
, -X- _ O
respiratory -X- _ B-Outcome
syncytial -X- _ I-Outcome
virus -X- _ I-Outcome
continues -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
potentially -X- _ I-Outcome
fatal -X- _ I-Outcome
in -X- _ I-Outcome
immunocompromised -X- _ I-Outcome
populations. -X- _ I-Outcome
In -X- _ O
this -X- _ O
review -X- _ O
, -X- _ O
we -X- _ O
discuss -X- _ O
the -X- _ O
incidence -X- _ O
of -X- _ O
respiratory -X- _ O
syncytial -X- _ O
viral -X- _ O
infections -X- _ O
, -X- _ O
risk -X- _ O
factors -X- _ O
associated -X- _ O
with -X- _ O
progression -X- _ O
from -X- _ O
upper -X- _ O
respiratory -X- _ O
tract -X- _ O
infection -X- _ O
to -X- _ O
lower -X- _ O
respiratory -X- _ O
tract -X- _ O
infection -X- _ O
, -X- _ O
other -X- _ O
complications -X- _ O
and -X- _ O
outcomes -X- _ O
( -X- _ O
including -X- _ O
mortality -X- _ O
) -X- _ O
, -X- _ O
management -X- _ O
strategies -X- _ O
, -X- _ O
and -X- _ O
prevention -X- _ O
strategies -X- _ O
in -X- _ O
patients -X- _ O
with -X- _ O
a -X- _ O
hematologic -X- _ O
malignancy -X- _ O
and -X- _ O
in -X- _ O
hematopoietic -X- _ O
cell -X- _ O
transplant -X- _ O
recipients -X- _ O
. -X- _ O

